Literature DB >> 28927482

Treating depressive episodes or symptoms in patients with schizophrenia.

Geeske van Rooijen1, Jentien Marloes Vermeulen1, Henricus Gerardus Ruhé1, Lieuwe de Haan1.   

Abstract

Depressive episodes or symptoms occur frequently in patients with schizophrenia and may have far-reaching consequences. Despite the high prevalence rate and clinical relevance of this comorbidity, knowledge about treatment options is still limited. The aim of this review is to provide an overview of the literature concerning treatment options for depressive episodes or symptoms in schizophrenia. Based on the current evidence, we present a stepwise treatment approach. The first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider lowering the dosage, since increased blockade of the dopamine D2 receptors may be associated with a worse subjective sense of well-being and dysphoria. A second step is to consider switching antipsychotics, since there are indications that some antipsychotics (including sulpiride, clozapine, olanzapine, aripiprazole, quetiapine, lurasidone, or amisulpride) are slightly more effective in reducing depressive symptoms compared to other antipsychotics or placebo. In the case of a persistent depressive episode, additional therapeutic interventions are indicated. However, the evidence is indecisive regarding the treatment of choice: either starting cognitive-behavioral therapy or adding an antidepressant. A limited number of studies examined the use of antidepressants in depressed patients with schizophrenia showing modest effectiveness. Overall, additional research is needed to determine the most effective treatment approach for patients with schizophrenia and depressive episodes.

Entities:  

Keywords:  Schizophrenia; antipsychotics; comorbid depression; neurobiology; treatment

Mesh:

Substances:

Year:  2017        PMID: 28927482     DOI: 10.1017/S1092852917000554

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  3 in total

1.  Guanosine ameliorates positive symptoms of schizophrenia via modulating 5-HT1A and 5-HT2A receptors.

Authors:  Yu Mao; Yao Xing; Jie Li; Dong Dong; Shoude Zhang; Zhenjiang Zhao; Jingli Xie; Rui Wang; Honglin Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 2.  Trichotillomania and Trichophagia: Modern Diagnostic and Therapeutic Methods.

Authors:  Hanna Cisoń; Aleksandra Kuś; Ewa Popowicz; Marta Szyca; Adam Reich
Journal:  Dermatol Ther (Heidelb)       Date:  2018-08-11

3.  Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets.

Authors:  Bozhi Yuan; Mei Yuan
Journal:  Comput Math Methods Med       Date:  2022-02-22       Impact factor: 2.238

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.